On Biostatistics and Clinical Trials
CQ's web blog on the issues in biostatistics and clinical trials.
Tuesday, August 15, 2023
Platform trials in action beyond oncology trials
›
One of the complex innovative designs is the study with 'Master protocol' that has been getting popularity in recent years. Master p...
2 comments:
Tuesday, August 01, 2023
Mediation Analysis vs. Landmark Analysis for Clinical Trial Data
›
Mediation analysis and Landmark analysis are two valuable statistical tools in different contexts, providing insights into different aspects...
Monday, July 24, 2023
Win Ratio and its application in clinical trials
›
The win ratio is a method for examining composite endpoints in clinical trials. It was introduced in 2012 by Dr Pocock and has since been ...
Friday, July 07, 2023
GCP violation and tampering with evidence
›
Last week, biotech company BioXcel reported positive efficacy results of their investigational product Igalmi in the treatment of Alzheimer...
1 comment:
Monday, June 26, 2023
Placebo Effect versus Nocebo Effect
›
In placebo-controlled clinical trials, a placebo refers to an inactive or inert substance or treatment that has no specific therapeutic effe...
Wednesday, June 21, 2023
SAE reporting - from non-serious AE to serious AE - one event or two events?
›
An adverse event is any undesirable experience associated with the use of a medical product in a patient. The event is serious (therefore se...
1 comment:
‹
›
Home
View web version
